CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16<sup>th</sup> Annual Meeting of the Association for Cancer Immunotherapy

Beck, Jan D.; Birtel, Matthias; Reidenbach, Daniel; Salomon, Nadja; Diken, Mustafa

doi:10.1080/21645515.2018.1504526

Human Vaccines & Immunotherapeutics

2018

DOI: 10.1080/21645515.2018.1504526

|View full text |Cite

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16^th Annual Meeting of the Association for Cancer Immunotherapy

Jan D. Beck

Matthias Birtel

Daniel Reidenbach

et al.

Abstract: The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's largest meeting series of its kind, took place in Mainz, Germany from 15-17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto "Pushing Frontiers in Cancer Immunotherapy". This meeting report is a summary of some of the CIMT 2018 highlights.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Book1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 85 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Oncology and palliative care

2019

Oxford Handbook of Palliative Care

View full text Add to dashboard Cite

This chapter provides an overview of current oncology practice as it pertains to palliative care. It covers the care of patients undergoing oncological interventions including some of the newer biological treatments and includes the management of the common side effects associated with the management of solid tumours in adults. It includes a succinct summary of the current management of common cancers. Cancer is an important cause of morbidity and mortality, particularly in industrialized countries. Currently in the UK, one person in two will be diagnosed with some form of cancer during their lifetime and one in four will die of the disease. Cancer incidence increases exponentially with age; with increasing life expectancy, cancer will become an even more common problem in the future. Cancers may develop in all body tissues. The chapter reviews the various ways that the cells that form cancers can be differentiated from cells in normal tissues.

show abstract

Oncology and palliative care

2019

Oxford Handbook of Palliative Care

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16^th Annual Meeting of the Association for Cancer Immunotherapy

Cited by 1 publication

References 85 publications

Oncology and palliative care

Oncology and palliative care

Contact Info

Product

Resources

About

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

Cited by 1 publication

References 85 publications

Oncology and palliative care

Oncology and palliative care

Contact Info

Product

Resources

About

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16^th Annual Meeting of the Association for Cancer Immunotherapy